Retirement Systems of Alabama Sells 745 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Retirement Systems of Alabama lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 0.6% during the second quarter, HoldingsChannel.com reports. The fund owned 124,210 shares of the company’s stock after selling 745 shares during the period. Retirement Systems of Alabama’s holdings in Neurocrine Biosciences were worth $17,100,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of NBIX. Vanguard Group Inc. lifted its stake in shares of Neurocrine Biosciences by 2.3% in the 1st quarter. Vanguard Group Inc. now owns 9,930,926 shares of the company’s stock valued at $1,369,673,000 after acquiring an additional 220,598 shares during the last quarter. Brown Advisory Inc. raised its position in Neurocrine Biosciences by 2.2% in the fourth quarter. Brown Advisory Inc. now owns 1,113,413 shares of the company’s stock valued at $146,703,000 after purchasing an additional 23,831 shares during the last quarter. Los Angeles Capital Management LLC raised its position in Neurocrine Biosciences by 66.0% in the fourth quarter. Los Angeles Capital Management LLC now owns 918,391 shares of the company’s stock valued at $121,007,000 after purchasing an additional 364,986 shares during the last quarter. Vestal Point Capital LP acquired a new stake in shares of Neurocrine Biosciences during the fourth quarter valued at about $105,408,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Neurocrine Biosciences by 10.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 686,835 shares of the company’s stock worth $90,497,000 after purchasing an additional 63,568 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Transactions at Neurocrine Biosciences

In related news, insider Ingrid Delaet sold 273 shares of the company’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $147.70, for a total transaction of $40,322.10. Following the completion of the sale, the insider now owns 6,607 shares in the company, valued at $975,853.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Stephen A. Sherwin sold 40,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $133.46, for a total value of $5,338,400.00. Following the completion of the transaction, the director now directly owns 26,504 shares of the company’s stock, valued at $3,537,223.84. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Ingrid Delaet sold 273 shares of Neurocrine Biosciences stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $147.70, for a total value of $40,322.10. Following the sale, the insider now owns 6,607 shares in the company, valued at $975,853.90. The disclosure for this sale can be found here. Insiders sold a total of 111,798 shares of company stock valued at $16,014,496 over the last ninety days. 4.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts recently commented on NBIX shares. Canaccord Genuity Group lifted their target price on shares of Neurocrine Biosciences from $154.00 to $164.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Jefferies Financial Group boosted their price objective on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a research note on Monday, August 19th. Citigroup raised their target price on Neurocrine Biosciences from $150.00 to $158.00 and gave the stock a “neutral” rating in a research report on Friday, August 2nd. UBS Group upped their price target on Neurocrine Biosciences from $174.00 to $193.00 and gave the company a “buy” rating in a research report on Tuesday, May 28th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a report on Thursday, August 1st. Six analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $161.32.

Neurocrine Biosciences Stock Up 0.2 %

Shares of NASDAQ:NBIX opened at $152.81 on Friday. Neurocrine Biosciences, Inc. has a twelve month low of $103.63 and a twelve month high of $157.98. The stock’s 50 day moving average is $143.56 and its 200-day moving average is $139.26. The firm has a market capitalization of $15.38 billion, a price-to-earnings ratio of 42.10 and a beta of 0.37.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Thursday, August 1st. The company reported $0.63 earnings per share for the quarter, missing the consensus estimate of $1.15 by ($0.52). Neurocrine Biosciences had a return on equity of 14.86% and a net margin of 16.00%. The business had revenue of $590.20 million for the quarter, compared to analyst estimates of $545.98 million. During the same quarter in the previous year, the company posted $0.95 EPS. The business’s quarterly revenue was up 30.4% on a year-over-year basis. Equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.22 earnings per share for the current fiscal year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.